DIPG TRIAL RESULTS PRESENTED AT ASCO 2021

Dr. Mark Souweidane Presents Interim Phase 1 Dose-Escalation Data for Omburtamab for DIPG

We are so proud to share that Dr. Mark Souweidane, in partnership with Y-mAbs Therapeutics, Inc., had the honor of presenting interim phase 1 dose-escalation data for omburtamab for diffuse intrinsic pontine glioma (“DIPG”) at the American Society of Clinical Oncology (“ASCO”) Virtual Annual Meeting. We are grateful to the American Society of Clinical Oncology for the opportunity to share this great work.

READ MORE

Share This Post